BeOne Medicines Ltd.
ONC Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$366.06
KIRA · Stoqly’s AI analyst, in plain words
- BeOne Medicines Ltd. had $5.3B of revenue in fiscal 2025, up 40.2% on the year before. Over five years, revenue changed +76.8% a year on average.
- Its operating margin was 8.4%, up 23.3 pts: of every 100 in sales, about 8 is left after running the business.
- BeOne Medicines Ltd. made $287M of net profit in fiscal 2025.
- Free cash flow was $942M in fiscal 2025, 17.6% of revenue.
- BeOne Medicines Ltd. has $3.7B more cash than debt.
Market cap
$551.0B
P/E
—
Revenue
$5.3B
Net income
$287M
Free cash flow
$942M
Operating margin
8.4%
BeOne Medicines Ltd. in 30 seconds · fiscal 2025
Are sales growing?
+40.2%
Yes. Sales grew 40.2% last year.
Does it make a profit?
5.4%
A little. It keeps 5.4% of every sale as profit.
Does profit turn into cash?
17.6%
Yes. 17.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
What BeOne Medicines Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- BeOne Medicines Ltd.
- CIK
- 0001651308
BeOne Medicines Ltd. · ONC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.2B | $1.4B | $2.5B | $3.8B | $5.3B |
| Revenue growth | 280.8% | 20.4% | 73.7% | 55.0% | 40.2% |
| Net interest income | −$15.8M | $52.5M | $74.0M | — | — |
| Gross margin | 86.0% | 79.8% | 84.5% | 84.4% | 87.5% |
| Operating margin | −122.3% | −126.4% | −49.1% | −14.9% | 8.4% |
| Net income | −$1.5B | −$2.0B | −$882M | −$645M | $287M |
| Net margin | −123.9% | −141.5% | −35.9% | −16.9% | 5.4% |
| Diluted EPS | −$1.21 | −$1.49 | −$0.65 | −$0.47 | $0.19 |
| Cash | |||||
| Cash from operations | −$1.3B | −$1.5B | −$1.2B | −$141M | $1.1B |
| Capital expenditure | $263M | $325M | $562M | $493M | $186M |
| Free cash flow | −$1.6B | −$1.8B | −$1.7B | −$633M | $942M |
| FCF margin | −132.8% | −128.7% | −69.9% | −16.6% | 17.6% |
| Share count change | 11.2% | 11.2% | 1.2% | 0.9% | 7.8% |
| Debt and strength | |||||
| Cash and short-term investments | $6.6B | $4.5B | $3.2B | $2.6B | $4.5B |
| Debt incl. finance leases | $630M | $538M | $886M | $1.9B | $845M |
| Shareholders' equity | $6.1B | $4.4B | $3.5B | $3.3B | $4.4B |
| Net debt / EBITDA | — | — | — | — | −6.3x |
| Current ratio | 4.8x | 3.5x | 2.3x | 1.8x | 3.4x |
| Interest coverage | −49.2x | −82.5x | −276.7x | −26.1x | 7.7x |
| Returns and quality | |||||
| Return on capital | −786.0% | −365.7% | −76.4% | −17.4% | 46.7% |
| Return on equity | −29.2% | −38.1% | −22.3% | −18.8% | 7.5% |
| Return on tangible equity | −24.0% | −46.1% | −25.3% | −19.7% | 6.7% |
| Piotroski F-score | 6 | 2 | 3 | 3 | 8 |
| Altman Z'' | 4.2 | 0.6 | −1.5 | −2.1 | 1.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$380M
12 insiders
Of sales under plans
96%
$364M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BeOne Medicines Ltd. · ONC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $366.06 a share, the company is worth $551.0B.
Source: SEC EDGAR XBRL filings (CIK 0001651308). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.